

PAIN MANAGEMENT: OPIOID USE IN HOSPITALS

Ni Made Amelia Ratnata Dewi¹, Ria Benkő^{1,2}, Zsófia Engi¹, Dezső Csupor^{1,3}, Réka Viola^{1,2}, Márta Csatornai¹, Mária Matuz^{1,2}

(1) Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary

(2) Central Pharmacy Department, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary

(3) Department of Rheumatology and Immunology, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary


Background and Objective

Opioids use is always a topic of concern due to the potential for overuse and abuse, as well as the limited access to them. However, there is a lack of hospital care data on opioid utilization in the literature, and there is no available data in Hungary. Therefore, our objective was to analyze opioid utilization in hospitals nationwide between 2015 and 2021.

Method



Data Source Sales data from IQVIA, national and regional bed days from National Health Insurance's Fund (NEAK)



Design Retrospective, observational




Focus Opioid analgesics (WHO's 'N02A' ATC group)




Main Outcome Measures DDD per 100 patient-days

Results


National Opioid Use in Hungary



Pattern of Opioid Use Stratified by Route of Administration




Regional Distribution of Opioid Use in Hungary in 2015 and 2021



Top Five Opioid Use in Hungary in 2015 and 2021

2015			2021		
Opioid	DDD per 100 patient days	%	Opioid	DDD per 100 patient days	%
TRAMADOL	5.17	62.92	TRAMADOL	3.44	42.34
FENTANYL	1.81	22.05	FENTANYL	2.10	25.91
MORPHINE	0.56	6.84	TRAMADOL & DEXKETOPROFEN	0.98	12.02
NALBUFIN	0.20	2.48	TRAMADOL AND PARACETAMOL	0.88	10.88
TRAMADOL & PARACETAMOL	0.11	1.37	MORPHINE	0.36	4.46

Regional Opioid Use in Hungary in 2021



Conclusion

The scale of opioid utilization in national hospitals has not changed over time, while pattern changed slightly. We observed the dominant use of weak oral opioids. Regional disparities were substantial.

Acknowledgment: ITM-NKFIA-TKP2021-EGA-32

Correspondence to:

Ni Made Amelia Ratnata Dewi
Institute of Clinical Pharmacy, University of Szeged
ameliadewi@unram.ac.id



SCAN HERE